济民健康
(603222)
| 流通市值：40.80亿 | | | 总市值：40.80亿 |
| 流通股本：5.25亿 | | | 总股本：5.25亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 337,635,982.5 | 163,097,985.21 | 685,962,950.12 | 544,718,299.64 |
| 营业收入 | 337,635,982.5 | 163,097,985.21 | 685,962,950.12 | 544,718,299.64 |
| 二、营业总成本 | 374,357,144.04 | 185,180,092.87 | 808,988,867.45 | 592,923,784.23 |
| 营业成本 | 215,017,897.82 | 108,204,176.92 | 472,971,795.98 | 348,045,819.3 |
| 税金及附加 | 5,589,805.57 | 2,769,606.42 | 12,968,894.93 | 9,574,899.43 |
| 销售费用 | 58,502,806.61 | 31,807,526.29 | 139,516,783.49 | 104,068,515.79 |
| 管理费用 | 56,065,965.48 | 27,707,853.9 | 111,527,422.8 | 84,572,171.24 |
| 研发费用 | 26,422,154.14 | 8,423,573.52 | 47,921,341.84 | 30,535,831.43 |
| 财务费用 | 12,758,514.42 | 6,267,355.82 | 24,082,628.41 | 16,126,547.04 |
| 其中:利息费用 | 12,296,716.33 | 6,014,337.35 | 23,987,806.37 | 17,930,270.81 |
| 其中:利息收入 | 473,029.46 | 239,822.37 | 2,517,553.91 | 2,177,819.32 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | -2,288.82 | -1,722.84 | -8,062.73 | -7,309.28 |
| 资产处置收益 | -6,311.07 | - | -68,690.52 | -68,690.52 |
| 资产减值损失(新) | -9,081,919.45 | -1,306,941.97 | -78,214,265.32 | -35,263,447.19 |
| 信用减值损失(新) | -1,428,764.41 | 65,121.83 | -10,334,977 | -9,561,131.3 |
| 其他收益 | 1,281,671.61 | 791,053.65 | 4,623,141.28 | 3,275,608.65 |
| 四、营业利润 | -45,958,773.68 | -22,534,596.99 | -207,028,771.62 | -89,830,454.23 |
| 加:营业外收入 | 200 | 8,730.4 | 1,766,055.81 | 1,955,358.43 |
| 减:营业外支出 | 1,970,341.32 | 166,899.58 | 28,685,946.16 | 2,832,970.95 |
| 五、利润总额 | -47,928,915 | -22,692,766.17 | -233,948,661.97 | -90,708,066.75 |
| 减:所得税费用 | 2,793,260.63 | 1,555,508.03 | 12,871,136.57 | -15,338,809.84 |
| 六、净利润 | -50,722,175.63 | -24,248,274.2 | -246,819,798.54 | -75,369,256.91 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -50,722,175.63 | -24,248,274.2 | -246,819,798.54 | -75,369,256.91 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -49,423,034.89 | -25,921,384.02 | -245,582,547.3 | -77,150,360.1 |
| 少数股东损益 | -1,299,140.74 | 1,673,109.82 | -1,237,251.24 | 1,781,103.19 |
| 扣除非经常损益后的净利润 | -47,657,919.34 | -25,888,474.77 | -219,785,531.02 | -76,535,346.56 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.1 | -0.05 | -0.47 | -0.15 |
| (二)稀释每股收益 | -0.1 | -0.05 | -0.47 | -0.15 |
| 八、其他综合收益 | -3,703,372.05 | -2,493,891.59 | 6,170,174.69 | 7,332,986.44 |
| 归属于母公司股东的其他综合收益 | -3,703,372.05 | -2,493,891.59 | 6,170,174.69 | 7,332,986.44 |
| 九、综合收益总额 | -54,425,547.68 | -26,742,165.79 | -240,649,623.85 | -68,036,270.47 |
| 归属于母公司股东的综合收益总额 | -53,126,406.94 | -28,415,275.61 | -239,412,372.61 | -69,817,373.66 |
| 归属于少数股东的综合收益总额 | -1,299,140.74 | 1,673,109.82 | -1,237,251.24 | 1,781,103.19 |
| 公告日期 | 2026-08-26 | 2026-04-30 | 2026-04-30 | 2025-10-31 |
| 审计意见(境内) | | | 带强调事项段的无保留意见 | |